Although an increasing number of prostate cancer (PCa) patients received holmium laser enucleation of the prostate (HoLEP) previously for benign prostatic obstruction (BPO), there is still no evidence regarding the outcomes of radical prostatectomy (RP) in this setting.
To assess functional and oncological results of RP in PCa patients who received HoLEP for BPO previously in a contemporary multi-institutional cohort.
A total of 95 patients who underwent RP between 2011 and 2019 and had a history of HoLEP were identified in two institutions. Functional as well as oncological follow-up was prospectively assessed and retrospectively analyzed.
RP following HoLEP compared with RP without previous transurethral surgery.
Patients with complete follow-up data were matched with individuals with no history of BPO surgery using propensity score matching. Complications were assessed using the Clavien-Dindo scale.
The median follow-up was 50.5 mo. We found no significant impact of previous HoLEP on positive surgical margin rate (14.0% [HoLEP] vs 18.8% [no HoLEP], p = 0.06) and biochemical recurrence-free survival (hazard ratio 0.74, 95% confidence interval [CI] 0.32-1.70, p = 0.4). Patients with a history of HoLEP had increased 1-yr urinary incontinence rates after RP. After adjusting for confounders, no significant impact of previous HoLEP was found (odds ratio [OR] 0.87, 95% CI 0.74-1.01; p = 0.07). Previous HoLEP did not hamper 1-yr erectile function recovery (OR 1.22, 95% CI 1.05-1.43; p = 0.01). Limitations include retrospective design and small sample size.
RP after previous HoLEP is surgically feasible, with low complication rates and no negative impact on biochemical recurrence-free survival. However, in a multivariable analysis, we observed significantly worse 1-yr continence rates in patients after previous HoLEP.
In the current study, we assessed the oncological and functional outcomes of radical prostatectomy in patients who underwent holmium laser enucleation of the prostate (HoLEP) previously due to prostatic bladder outlet obstruction. A history of HoLEP did not hamper oncological results, 1-yr continence, and erectile function recovery.
European urology focus. 2020 Sep 19 [Epub ahead of print]
Alexander Kretschmer, Elio Mazzone, Francesco Barletta, Riccardo Leni, Isabel Heidegger, Igor Tsaur, Roderick C N van den Bergh, Massimo Valerio, Giancarlo Marra, Veeru Kasivisvanathan, Alexander Buchner, Christian G Stief, Alberto Briganti, Francesco Montorsi, Derya Tilki, Giorgio Gandaglia, EAU-YAU Prostate Cancer Working Party
Department of Urology, Ludwig-Maximilians University of Munich, Munich, Germany. Electronic address: ., Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Department of Urology, Medical University Innsbruck, Innsbruck, Austria., Department of Urology and Pediatric Urology, Mainz University Medicine, Mainz, Germany., Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands., Department of Urology, CHUV, Lausanne, Switzerland., Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy., Division of Surgery and Interventional Science, University College London, London, UK., Department of Urology, Ludwig-Maximilians University of Munich, Munich, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital-Hamburg Eppendorf, Hamburg, Germany.